 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Binding protein
|
PDB id
|
|
|
|
1ilr
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
4 terms
|
 |
|
Biological process
|
immune response
|
3 terms
|
 |
|
Biochemical function
|
protein binding
|
3 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Eur J Biochem
227:838-847
(1995)
|
|
PubMed id:
|
|
|
|
|
| |
|
Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis-proline.
|
|
H.A.Schreuder,
J.M.Rondeau,
C.Tardif,
A.Soffientini,
E.Sarubbi,
A.Akeson,
T.L.Bowlin,
S.Yanofsky,
R.W.Barrett.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Interleukin-1 (IL-1) molecules are cytokines involved in the acute-phase
response against infection and injury. Three naturally occurring IL-1 molecules
are known, two agonists: IL-1 alpha and IL-1 beta, and one antagonist, the IL-1
receptor antagonist (IL-1ra). Although IL-1 action protects the organism by
enhancing the response to pathogens, its overproduction can lead to pathology
and has been implicated in disease states that include septic shock, rheumatoid
arthritis, graft versus host disease and certain leukemias. The crystal
structure of IL-1ra has been solved at 0.21-nm resolution by molecular
replacement using the IL-1 beta structure as a search model. The crystals
contain two independent IL-1ra molecules which are very similar. IL-1ra has the
same fold as IL-1 alpha and IL-1 beta. The fold consists of twelve beta-strands
which form a six-stranded beta-barrel, closed on one side by three beta-hairpin
loops. Cys69 and Cys116 are linked via a disulfide bond and Pro53 has been built
in the cis-conformation. Comparison of the IL-1ra structure with the IL-1 alpha
and IL-1 beta structures present in the Protein Data Bank shows that a putative
receptor interaction region, involving the N-terminus up to the beginning of
strand beta 1 and the loops D and G, is very different in the three IL-1
molecules. Other putative interaction regions, as identified with mutagenesis
studies, are structurally conserved and rigid, allowing precise and specific
interactions with the IL-1 receptor.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Karaca,
and
A.M.Bonvin
(2011).
A multidomain flexible docking approach to deal with large conformational changes in the modeling of biomolecular complexes.
|
| |
Structure, 19,
555-565.
|
 |
|
|
|
|
 |
S.Krishnan,
and
A.A.Raibekas
(2009).
Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization.
|
| |
Biophys J, 96,
199-208.
|
 |
|
|
|
|
 |
J.R.Alford,
B.S.Kendrick,
J.F.Carpenter,
and
T.W.Randolph
(2008).
High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics.
|
| |
J Pharm Sci, 97,
3005-3021.
|
 |
|
|
|
|
 |
J.R.Alford,
S.C.Kwok,
J.N.Roberts,
D.S.Wuttke,
B.S.Kendrick,
J.F.Carpenter,
and
T.W.Randolph
(2008).
High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization.
|
| |
J Pharm Sci, 97,
3035-3050.
|
 |
|
|
|
|
 |
R.F.Latypov,
D.Liu,
K.Gunasekaran,
T.S.Harvey,
V.I.Razinkov,
and
A.A.Raibekas
(2008).
Structural and thermodynamic effects of ANS binding to human interleukin-1 receptor antagonist.
|
| |
Protein Sci, 17,
652-663.
|
 |
|
|
|
|
 |
Z.Q.Wen,
X.Cao,
and
A.Vance
(2008).
Conformation and side chains environments of recombinant human interleukin-1 receptor antagonist (rh-IL-1ra) probed by raman, raman optical activity, and UV-resonance Raman spectroscopy.
|
| |
J Pharm Sci, 97,
2228-2241.
|
 |
|
|
|
|
 |
G.Vergoten,
and
J.P.Zanetta
(2007).
Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling.
|
| |
Glycoconj J, 24,
183-193.
|
 |
|
|
|
|
 |
M.B.Seefeldt,
C.Crouch,
B.Kendrick,
and
T.W.Randolph
(2007).
Specific volume and adiabatic compressibility measurements of native and aggregated recombinant human interleukin-1 receptor antagonist: density differences enable pressure-modulated refolding.
|
| |
Biotechnol Bioeng, 98,
476-485.
|
 |
|
|
|
|
 |
Z.Q.Wen
(2007).
Raman spectroscopy of protein pharmaceuticals.
|
| |
J Pharm Sci, 96,
2861-2878.
|
 |
|
|
|
|
 |
E.Y.Chi,
B.S.Kendrick,
J.F.Carpenter,
and
T.W.Randolph
(2005).
Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist.
|
| |
J Pharm Sci, 94,
2735-2748.
|
 |
|
|
|
|
 |
H.Tan,
G.Dan,
H.Gong,
and
L.Cao
(2005).
On-column refolding and purification of recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) expressed as inclusion body in Escherichia coli.
|
| |
Biotechnol Lett, 27,
1177-1182.
|
 |
|
|
|
|
 |
M.B.Seefeldt,
Y.S.Kim,
K.P.Tolley,
J.Seely,
J.F.Carpenter,
and
T.W.Randolph
(2005).
High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies.
|
| |
Protein Sci, 14,
2258-2266.
|
 |
|
|
|
|
 |
S.Roy,
R.Jung,
B.A.Kerwin,
T.W.Randolph,
and
J.F.Carpenter
(2005).
Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
|
| |
J Pharm Sci, 94,
382-396.
|
 |
|
|
|
|
 |
Y.Zhang,
S.Roy,
L.S.Jones,
S.Krishnan,
B.A.Kerwin,
B.S.Chang,
M.C.Manning,
T.W.Randolph,
and
J.F.Carpenter
(2004).
Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution.
|
| |
J Pharm Sci, 93,
3076-3089.
|
 |
|
|
|
|
 |
J.L.Barton,
R.Herbst,
D.Bosisio,
L.Higgins,
and
M.J.Nicklin
(2000).
A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities.
|
| |
Eur J Immunol, 30,
3299-3308.
|
 |
|
|
|
|
 |
J.K.Dattagupta,
A.Podder,
C.Chakrabarti,
U.Sen,
D.Mukhopadhyay,
S.K.Dutta,
and
M.Singh
(1999).
Refined crystal structure (2.3 A) of a double-headed winged bean alpha-chymotrypsin inhibitor and location of its second reactive site.
|
| |
Proteins, 35,
321-331.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
W.P.Arend,
M.Malyak,
C.J.Guthridge,
and
C.Gabay
(1998).
Interleukin-1 receptor antagonist: role in biology.
|
| |
Annu Rev Immunol, 16,
27-55.
|
 |
|
|
|
|
 |
A.L.Weckmann,
and
J.Alcocer-Varela
(1996).
Cytokine inhibitors in autoimmune disease.
|
| |
Semin Arthritis Rheum, 26,
539-557.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|